Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sentinel – Just Do It

Executive Summary

As FDA refines an approach to its Sentinel post-market drug safety surveillance project, "we will address issues of patient privacy and confidentiality [and] we will address the issues of the scientific accuracy and reliability of the data before we use it," Commissioner Andrew von Eschenbach says at a June 13 Brookings Institution conference on the issue. "On the other hand, in terms of implementing it, if we can identify the fatal flaws and address them, we should do that and must do that before we do it. But if it isn't a fatal flaw, it's just a flaw, a blemish, or a defect, it shouldn't stop us from doing it. It may impair us or prevent us from using it, but that's an important distinction." Sentinel is envisioned as a national network of electronic data systems that FDA could access to monitor the safety of drugs and medical devices (1"The Pink Sheet," May 26, 2008, p. 3)

You may also be interested in...



FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details

HHS unveiled the first phase of FDA's "Sentinel" post-market drug safety surveillance initiative with fanfare May 22, but stakeholders will have to wait a while for details on funding and the timing of a full-scale rollout

Color Additive Risk Evaluation Tool Qualified As New Medical Device Development Tool

A color additive evaluation tool for polymeric medical devices was approved as an MDDT under the FDA’s voluntary program.

CinCor Plans Baxdrostat Phase III Despite Phase II Miss In Uncontrolled Hypertension

With subgroup analysis that it claims shows efficacy in non-Hispanics and success in a previous Phase II in treatment-resistant hypertension, CinCor plans to outline Phase III plans to FDA in early 2023.

Latest News
See All
UsernamePublicRestriction

Register

PS049767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel